#HSCT

[hiscet]

for all this movie's faults they captured the humour of the games pretty well

[the-railroad-earth]

recent views ✨ trip to brunswick lake

[miriam-heddy]

911 tv Buck, Maddie, and 2 links to RL Research on Pediatric Sibling Stem-Cell Donors

If you're curious about what Buck and Maddie and Daniel might have experienced (including PTSD), you might find this interesting. (Caveat, all kids studied were 6 or more yrs old). If you don't read much in the way of research, just skip down to the Findings section (which has lots of quotes from kids).

Klippenstein ADW, Piotrowski CC, Winkler J, West CH. Growth in the face of overwhelming pressure: A narrative review of sibling donor experiences in pediatric hematopoietic stem cell transplant. J Child Health Care. 2023 Mar;27(1):60-77. doi: 10.1177/13674935211043680. Epub 2021 Sep 27. PMID: 34570621; PMCID: PMC9932621. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932621/

And if you're interested in the Medical Ethics ethics of it:

Wiesemann, C. (2022). Mediating the Risks of Mutual Care: Families and the Ethical Challenges of Sibling Bone Marrow Donation. In: Schües, C., Rehmann-Sutter, C., Jürgensen, M., Herzog, M. (eds) Stem Cell Transplantations Between Siblings as Social Phenomena. Philosophy and Medicine, vol 144. Springer, Cham. https://doi.org/10.1007/978-3-031-04166-2_

[102ki]

[isabelamarina766]

Hematopoietic stem cell transplantation is a sophisticated medical procedure that entails the infusion of hematopoietic stem cells to rejuvenate the bone marrow's capacity to generate blood cells.

[greenwoodbotanics10]

MS Mysteries Unlocked: Early Clues, Lifespan Secrets, and a Radical Cure?

MS Mysteries Unlocked Multiple Sclerosis (MS) is a complex and unpredictable disease—but what if we could crack its code? From strange first symptoms to groundbreaking stem cell treatments, here’s what science reveals (and what still remains a mystery).  The Weird First Signs of MS Your Doctor Warned You About MS doesn’t always announce itself loudly. Instead, it whispers through bizarre…

[gulshanwhydonate]

Traitement HSCT SEP Commencez à Faire une Collecte de Fonds ou à Faire un Don

La thérapie par cellules souches (aHSCT ou HSCT) n’est pas encore disponible aux Pays-Bas et n’est pas remboursée en tant que traitement pour les patients atteints de sclérose en plaques (SEP). La recherche scientifique montre que certaines formes de traitement de la SEP peuvent prévenir de nouvelles attaques et ralentir ou même arrêter la régression.

Cependant, l’objectif de la thérapie cellules souches (traitement HSCT de la SEP) est de « réinitialiser » le système immunitaire afin que les cellules inflammatoires de la SEP n’attaquent plus le cerveau. Les personnes atteintes de SEP active souffrent de ces attaques.

La thérapie par cellules souches (aHSCT) en tant que traitement de la SEP n’est disponible aux Pays-Bas que dans un contexte de recherche. Ce traitement est actuellement pratiqué dans d’autres pays (notamment en Russie, au Mexique, en Amérique et en Allemagne).

Traitement par Cellules Souches de La Sclérose en Plaques(SEP)

La thérapie par cellules souches, officiellement appelée “aHSCT” (également connue sous le nom de HSCT), est une transplantation autologue de cellules souches hématopoïétiques. Ce traitement utilise des cellules souches présentes dans la moelle osseuse et le sang, appelées cellules hématopoïétiques. Autologue signifie que l’on utilise ses propres cellules souches.

Il convient de noter que le traitement peut stabiliser la maladie et même restaurer la perte de fonction chez certaines personnes. Les meilleurs résultats ont été obtenus chez les personnes atteintes de la forme agressive précoce de la sclérose en plaques récurrente-rémittente (SEP-RR).

Collecter des Fonds pour la Greffe de Cellules Souches de La Sclérose en Plaques

La greffe de cellules souches pour la sclérose en plaques est un traitement vraiment coûteux. Le coût moyen d’une thérapie à base de cellules souches varie entre 5 000 et 50 000 euros. Avant d’envisager un traitement qui change leur vie, les patients doivent se renseigner de manière approfondie sur le processus. Cela leur permettra de prendre des décisions éclairées concernant le traitement par cellules souches de la sclérose en plaques et son impact potentiel sur leur santé. Parmi les facteurs les plus importants que les patients doivent prendre en compte figurent la qualité des cellules qu’ils obtiennent, l’établissement où ils sont traités et le coût.

Étant donné que les patients ne peuvent pas opter pour une assurance maladie pour le traitement par cellules souches de la SEP, ils peuvent certainement choisir de faire appel au crowdfunding pour collecter des fonds pour leurs soins de santé. Grâce au crowdfunding, les patients n’ont qu’à s’inscrire sur une plateforme de collecte de fonds et à collecter de l’argent pour payer leurs factures médicales. Les plateformes de collecte de fonds permettent aux personnes du monde entier de faire des dons grâce auxquels les patients atteints de sclérose en plaques peuvent trouver une nouvelle lueur d’espoir pour une meilleure santé.

Lisez notre article pour avoir plus d’idées sur la façon dont vous pouvez commencer à Collecter des Fonds pour les Soins Médicaux.

Rejoignez La Communauté De Collecte De Fonds De WhyDonate

51,340+

Les Cagnotte Commencé

1M+

Visiteurs Mensuels Site Web

876,175+

Donateurs Actifs

4.8/5

Note Moyenne Des Avis

WhyDonate Fundraising Stories

Aidez Jerry à lutter contre la SP – Collecte de fonds pour le traitement HTSC

Supposons que vous ayez 26 ans et que vous soyez donc dans la force de l’âge. Vous bougez, faites de l’exercice et travaillez beaucoup et dur. Et puis tout à coup, lorsque vous visitez le neurologue, on vous dit que vous souffrez de sclérose en plaques récurrente-rémittente, ou SEP-RR en abrégé. Et sous une forme progressive aussi. C’est le cauchemar de tout le monde. Pour Jerry Huizinga, aujourd’hui âgé de 31 ans, c’est devenu une dure réalité. Son monde et celui de sa femme Anne se sont effondrés. Ma seule chance est un traitement par cellules souches HSCT. Il coûte 60 000 € et je n’ai pas cet argent.

WhyDonate Fundraising Stories

Greffe de cellules souches pour Kel

Pour moi, ma mission s’est terminée juste avant qu’elle n’ait été initialement prévue. Enfin, le diagnostic définitif de SEP a été posé. Dans les années qui ont suivi, j’ai eu plusieurs crises. La combinaison d’un travail à plein temps, devenir mère et tout le reste est devenue trop lourde. En suivant le traitement aHSCT, je peux être sûr de pouvoir vraiment garder mon emploi. En plus de gravir les « sommets du monde » avec ma famille, c’est aussi l’un de mes plus grands souhaits.

900 donateurs ont collecté plus de 65 000 € pour ces Crowdfunding Medical Care.

WhyDonate Fundraising Stories

Campagne de collecte Greffe de cellules souches (HSCT Mexique) Siggy

Je m’appelle Siggy, j’ai la SEP (PPMS) depuis 10 ans. La seule solution est la greffe de cellules souches (GCSH) pour arrêter la SEP. Je peux très bien me débrouiller avec ma main (bras) droite, mais il faut qu’il continue à le faire ! Cela pourrait devenir une réalité après ce traitement.

Malheureusement, cela n’est pas possible aux Pays-Bas et n’est pas remboursé par l’assurance maladie. Je veux faire ça au Mexique. Les frais de ce traitement sont de 55 000 €, ce qu’il me reste, la Fondation donne à quelqu’un qui, comme moi, veut faire ce traitement.

WhyDonate Fundraising Stories

Aidez Jerry à lutter contre la SP – Collecte de fonds pour le traitement HTSC

Supposons que vous ayez 26 ans et que vous soyez donc dans la force de l’âge. Vous bougez, faites de l’exercice et travaillez beaucoup et dur. Et puis tout à coup, lorsque vous visitez le neurologue, on vous dit que vous souffrez de sclérose en plaques récurrente-rémittente, ou SEP-RR en abrégé. Et sous une forme progressive aussi. C’est le cauchemar de tout le monde. Pour Jerry Huizinga, aujourd’hui âgé de 31 ans, c’est devenu une dure réalité. Son monde et celui de sa femme Anne se sont effondrés. Ma seule chance est un traitement par cellules souches HSCT. Il coûte 60 000 € et je n’ai pas cet argent.

WhyDonate Fundraising Stories

Greffe de cellules souches pour Kel

Pour moi, ma mission s’est terminée juste avant qu’elle n’ait été initialement prévue. Enfin, le diagnostic définitif de SEP a été posé. Dans les années qui ont suivi, j’ai eu plusieurs crises. La combinaison d’un travail à plein temps, devenir mère et tout le reste est devenue trop lourde. En suivant le traitement aHSCT, je peux être sûr de pouvoir vraiment garder mon emploi. En plus de gravir les « sommets du monde » avec ma famille, c’est aussi l’un de mes plus grands souhaits.

900 donateurs ont collecté plus de 65 000 € pour ces Crowdfunding Medical Care.

WhyDonate Fundraising Stories

Campagne de collecte Greffe de cellules souches (HSCT Mexique) Siggy

Je m’appelle Siggy, j’ai la SEP (PPMS) depuis 10 ans. La seule solution est la greffe de cellules souches (GCSH) pour arrêter la SEP. Je peux très bien me débrouiller avec ma main (bras) droite, mais il faut qu’il continue à le faire ! Cela pourrait devenir une réalité après ce traitement.

Malheureusement, cela n’est pas possible aux Pays-Bas et n’est pas remboursé par l’assurance maladie. Je veux faire ça au Mexique. Les frais de ce traitement sont de 55 000 €, ce qu’il me reste, la Fondation donne à quelqu’un qui, comme moi, veut faire ce traitement.

WhyDonate Fundraising Stories

Aidez Jerry à lutter contre la SP – Collecte de fonds pour le traitement HTSC

Supposons que vous ayez 26 ans et que vous soyez donc dans la force de l’âge. Vous bougez, faites de l’exercice et travaillez beaucoup et dur. Et puis tout à coup, lorsque vous visitez le neurologue, on vous dit que vous souffrez de sclérose en plaques récurrente-rémittente, ou SEP-RR en abrégé. Et sous une forme progressive aussi. C’est le cauchemar de tout le monde. Pour Jerry Huizinga, aujourd’hui âgé de 31 ans, c’est devenu une dure réalité. Son monde et celui de sa femme Anne se sont effondrés. Ma seule chance est un traitement par cellules souches HSCT. Il coûte 60 000 € et je n’ai pas cet argent.

Comment démarrer une campagne ?

Suivez ces 4 étapes simples

1. Lancer une campagne Inscrivez-vous sur Whydonate et créez votre campagne en quelques minutes. Inscrivez-vous en tant que personne ou organisation.

2. Partagez votre campagne Partagez votre campagne par e-mail, WhatsApp et d’autres canaux de médias sociaux pour atteindre autant de donateurs que possible.

3. Recevoir les dons Les dons sont versés automatiquement sur votre compte bancaire sur une base mensuelle sans aucun coût de plateforme.

4. Remerciez vos donateurs Personnalisez l’e-mail de remerciement automatisé ou envoyez un message personnel à vos donateurs via le tableau de bord Whydonate.

Commencez Une Collecte De Fonds Gratuite Pour Le Traitement HSCT MS

 Traitement HSCT

 HSCT pour la SEP

 Qu’est-ce que le traitement HSCT

 HSCT Mexique

 HSCT Sclérose En Plaques

Pour s'infos: https://whydonate.com/fr/traitement-hsct-ms-collecte-de-fonds/

Keywords;  thérapie cellules souches, Traitement HSCT, médias sociaux, Crowdfunding Medical Care, collecter des fonds, collecte de fonds

[covid-safer-hotties]

Reference saved in our archive

Masking by hospital staff dropped the instances of respiratory infection during a hospital stay from 22% in patients to just a hair over 2%.

Abstract Patients undergoing allogenic hematopoietic stem cell transplantation (allo-HSCT) are highly susceptible to infections. The consequent use of masks on wards for allo-HSCT has been controversial in the past decades and was not common before the COVID-19 pandemic. We retrospectively compared incidence and outcomes of viral respiratory infections during allo-HSCT on our specialized ward between 01/2018 and 09/2020 to the era of FFP2 masking between 10/2020 and 10/2022 covering similar seasons of the year. Each group consisted of 150 matched patients. The usage of FFP2 masks reduced the incidence of viral respiratory infections from 22.1 to 2.1% (p < 0.005). This reduced the time on ward from a median of 26 days to 23.5 days (p = 0.002). It also resulted in less use of CT-scans (p = 0.003) and bronchoalveolar lavage procedures (p = 0.057). Median time to proof of infection was 21 days after admission in both groups. No difference was detected in progression free survival, hospital survival or non-relapse mortality (p = 0.78). Our retrospective results indicate that FFP2 masks worn by patients and hospital staff may help to significantly reduce the incidence of viral respiratory infections, including COVID-19, shorten the in-hospital time, and reduce costs without affecting survival.

[bpod-bpod]

Blood to Brain

Bone marrow-derived (haematopoietic) stem cell transplants (HSCT), such as may be given for treating leukaemia, are being investigated as a means of delivering therapeutic proteins to the central nervous system. In this study, mice deficient in a protein called progranulin – mimicking the cause of neurological disease in humans – had levels restored by HSCT

Read the published research article here

Image from work by Pasqualina Colella and colleagues

Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA

Video originally published with a Creative Commons Attribution 4.0 International (CC BY 4.0)

Published in Nature Communications, July 2024

You can also follow BPoD on Instagram, Twitter and Facebook

[usafphantom2]

NASA Used the SR-71 that they were loaned to by the Air Force for research in 1995. This research helped produce the test plane introduced today X-59.

Sonic Boom Mitigation

Author: SR Admin / Categories: NASA SR-71 /

A flight experiment was conducted at the NASA's Dryden Flight Research Center in Edwards, California, using an SR-71, an F-16XL, and a YO-3A airplane (see Figure 1) to study the propagation of sonic booms. This work was geared toward developing a high-speed civil transport (HSCT) aircraft for operational use early in the next century.

At supersonic speeds, an aircraft generates numerous shock waves that emanate from such major components as the nose, canopy, inlets, wings, and vertical tails. These multiple shock waves tend to merge into a strong bow shock and a strong tail shock as they propagate through the atmosphere. At present, supercomputers and wind tunnels are used to predict the structures of these shock waves, but only within a few body lengths of the aircraft. Other computational techniques are then used to determine the propagation and merging of these shock waves down to ground level. To verify and enhance the quality of these computational propagation techniques, a database of sonic-boom measurements at various altitudes was gathered for use by the aerospace industry, universities, and NASA research centers. These organizations will use the enhanced computational techniques in the design of for the full article, click here thesr71blackbird.com/History/CIA/so…

@Habubrats71 via X

[hiscet]

fully choosing to believe that kay just lies about not stealing anything because she's smart enough to not blatantly admit that to a lawyer

[jcsmicasereports]

Hydroxyurea and Sperm Abnormalities in Patients with Sickle Cell Disease by Dr. Salma M. AlDallal in Journal of Clinical Case Reports Medical Images and Health Sciences 

ABSTRACT

Hydroxyurea is a key treatment option for patients having sickle cell disease. Although the treatment has been effective in improving the survival rate, new concerns over improving quality of life are forthcoming due to spermatogenesis-related toxicities and teratogenic effects. The available evidence shows that hydroxyurea might exacerbate the existing sperm abnormalities. There is a lack of comprehensive, systemic evidence to demonstrate the precise effects and role of hydroxyurea on sperm abnormalities in patients with sickle cell disease. Patients and healthcare providers require accurate and extensive information on sperm-related toxicities to make informed decisions. Here, I discuss the effects of hydroxyurea (HU) on sperm parameters, clinical study evidence, and treatment options available for fertility preservation in these patients.

Keywords: Sickle cell disease, Hydroxyurea, Sperm abnormalities

INTRODUCTION

Sickle cell disease (SCD) is a group of genetic blood disorders that leads to abnormality in hemoglobin. In patients with SCD, newer medical treatments have improved survival rates and quality of life along with a reduced disease-related morbidity. Consequently, the focus of the treatment is diverging to encompass the reproductive issues associated with these treatments. In adolescents and young patients with SCD, sexual maturation is delayed by 1.5-2 years [1, 2], and approximately 24% of SCD patients may have hypogonadism, infertility, erectile dysfunction, and poor libido [3]. The issues related to fertility and reproductive organs in SCD are either related to disease or to the treatments used to treat SCD-related morbidity.

Reduced SCD-related morbidity has been observed with treatments like hydroxyurea (HU) and hematopoietic stem cell transplantation (HSCT). However, adverse effects and toxicities associated with these therapies are a concern. HU use has been associated with sperm abnormalities and teratogenic effects [4, 5]. However, HU affects rapidly dividing cells, raising concerns about related toxicities. Therefore, it is essential to evaluate if there is an exacerbation of fertility problems in men with SCD. This review summarizes the spermatogenic effects of HU in males with SCD.

Fertility issues in males with SCD

Some of the disease-related fertility issues observed in patients with SCD are hypogonadism, sperm abnormalities, erectile dysfunction, delay in sexual maturation, and abnormal hormone (testosterone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH)) levels.

The sperm abnormality rate is as high as 91% in males with SCD [6]. Although some reports attribute sperm abnormalities to delayed puberty in males with SCD [7], some others attribute it to testicular infarction or hypogonadism. It is also worth noting that sperm abnormalities also exist with normal testosterone, FSH, and LH levels [8].

In addition to sperm abnormalities, the incidence of erectile dysfunction in men with SCD is reported to be 21%–35% [9-11]. Also, a decrease in semen is reported in men with SCD [12]. Laboratory findings show low testosterone levels with variable FSH and LH levels. Moreover, abnormalities in accessory organs like seminal vesicles and prostate glands may be present due to recurrent urinary tract infections. These reproductive issues are exacerbated by therapies like HU, which have therapeutic effects through impairing DNA synthesis.

HU in treatment of SCD

HU is approved for the prevention of vaso-occlusive pain in SCD. HU is a ribonucleotide reductase inhibitor that impairs DNA synthesis due to its S-phase-specific cytotoxic action. It is an antimitotic agent that can impair human spermatogenesis. It is a disease-modifying therapy that decreases episodes of acute pain and acute chest syndrome in SCD patients [13]. The HU therapy increases the fetal haemoglobin, which does not sickle under low oxygen tension. Low-dose HU therapy (10 mg/kg/day) has been effective in improving clinical and hematological parameters, reducing painful crises, and reducing blood transfusion requirements in SCD patients. Although HU has improved the quality of life and survival rate, its use is limited by its toxicities, particularly its effect on fertility parameters.

SCD itself manifests in some abnormalities like spermatogenesis, and seminal fluid, which may be exacerbated with cytotoxic HU therapy. HU is associated with abnormal sperm morphology [14] and a decrease in sperm count [14-16] in patients with SCD. At a therapeutic dose, it has short-lived, irregular cytotoxic effects on dividing cells [4]. Since it is an antimetabolite, it is hypothesized to have a risk of affecting sperm development [4]. These effects are often brief and reversible with discontinuation of the drug administration.

Infertility in Men with SCD

Although HU treatment has improved outcomes in patients with SCD, it has been associated with effects on spermatogenesis and teratogenicity, for example, testicular atrophy, hypogonadism, decreased sperm count, abnormal sperm motility, and abnormal sperm morphology.

Hypogonadism

Male hypogonadism is decreased functional activity of the gonads that results in a testosterone deficiency. Testosterone deficiency can cause infertility, muscle wasting, and the absence of secondary sex characteristics. The mechanism for the cause of hypogonadism may be primary gonadal failure [17-19], repeated testicular infarction [20], zinc deficiency [21, 22], and partial hypothalamic hypogonadism [23].

Abnormal spermatogenesis

Impaired spermatogenesis has been reported in male patients with SCD receiving HU therapy, which leads to testicular atrophy, oligozoospermia (low sperm count), abnormal sperm morphology, and azoospermia (decreased sperm motility) [6, 15, 16, 24-31]. It is yet unclear if the abnormalities directly affect HU therapy. However, some researchers believe that the extent of sperm abnormalities might be associated with the length of HU therapy [29, 30]. Since SCD is a genetic condition manifesting at an early age, the duration of HU therapy remains long.

Abnormal Hormone level

A few studies have reported altered levels of testosterone and dihydrotestosterone, FSH, and LH in patients with SCD [12, 32, 33]. The testosterone levels have a direct effect on fertility [6], reduction in semen volume, sperm count, and motility in sickle cell male patients [10].

Priapism

Priapism is defined as a prolonged and lasting continued penile erection unrelated to sexual interest or stimulation [34]. The prevalence of priapism and erectile dysfunction in patients with SCD is 45% and 30%, respectively [35-37].

Penile erection is regulated by the neurotransmitter nitric oxide (NO). In SCD patients, the bioavailability of NO is decreased, disturbing the relaxation of penile smooth muscle [38, 39]. Also, the adenosine regulation pathway might be contributing to the pathophysiology of priapism in SCD patients.

Studies evaluating the effect of HU therapy on spermatogenesis SCD patients

Several studies have reported the role of HU in the exacerbation of various sperm abnormalities in patients with SCD. A non-interventional study (ESCORT-HU-European Sickle Cell Disease Cohort-Hydroxyurea) evaluated safety, morbidity, and mortality in 422 SCD patients of age 15years and older treated with HU [40, 41]. The study reported 67 pre-treatment and 24 during treatment semen analyses. Before treatment with HU, 49% of sperm analyses were normal, and 25% were abnormal (at least 1 abnormality: sperm mobility, sperm count, appearance). The rate of abnormalities during HU treatment increased to 50%. The abnormalities observed were asthenospermia, hypospermia, oligospermia, azoospermia, and atypical forms. These results confirmed that sperm abnormalities are exacerbated after HU treatment.

A prospective, Phase 4 multicentre study called HYDREP (NCT01609192) assessed the effect of HU treatment in patients with SCD [42]. The study reported a significant and rapid decrease in mean total sperm count from 129.8 million at baseline to 24.1 million at month 6. Furthermore, 86% of patients had an abnormal value of total sperm count at month 6 compared to only 40% at baseline. Researchers also found that 6 months of HU treatment did not affect the semen volume. They reported that the treatment of SCD with HU causes significant abnormality in spermatogenesis. After treatment, the number of men with abnormal total sperm count and cryptozoospermia increased to 30 patients and 5 patients, respectively. Additionally, six patients (17%) became azoospermic, and 19 were oligozoospermic.

An unmatched case-control study in Nigeria compared serum testosterone concentration among 47 patients with hemoglobin phenotype SS and 28 volunteers with hemoglobin phenotype AA [43]. The concentrations of serum testosterone in 44 of 47 hemoglobin phenotype SS patients were significantly lower as compared to 7 of 28 volunteers with hemoglobin phenotype AA.

A group of researchers evaluated the effect of long-term HU treatment from childhood to adult age in four patients [44]. These patients were receiving HU treatment for more than 8 years. They observed that two patients experienced severe oligozoospermia and two azoospermia. The treatment exposure in patients experiencing oligozoospermia was shorter (8 and 9 years) compared to patients experiencing azoospermia (12 and 15 years). There was also an increased percentage of abnormal spermatozoa morphology in these patients.

Furthermore, a study assessed spermatogonial quantity in prepubertal patients who received alkylating agents to compare with patients who received non-alkylating agents. They demonstrated that the quantity of spermatogonia per transverse tubular cross-section was significantly low in patients with SCD receiving hydroxyurea (0.3 ± 0.6, n = 6; P = 0.008) [45].Contrarily, a recent study reported no difference in semen volume, sperm concentration, total sperm count, or spermatozoa motility, morphology, and vitality between patients with SCD who received HU before puberty and who did not receive HU during puberty [46].

Semen analysis

A significant reduction in sperm density, ejaculate volume, sperm motility was reported in the SCD patients compared to the control subjects [43]. Likewise, some former studies that performed semen analysis in men with SCA reported a reduction in sperm motility, sperm density, and sperm morphology [44]. Similarly, Osegbe et al. and Agbaraji et al. analyzed sperm density, motility, morphology, and semen volume in patients with SCD. They reported a decrease in sperm motility, sperm density, and abnormal morphology in patients with SCD. [12, 47] Osegbe et al. observed no difference in semen volume [33]. Additionally, Friedman et al. reported oligospermia in 3 out of 4 patients with SCD [47].

Similar to Osegbe et al., a recent study also reported a normal volume of ejaculate in 75% of the samples of SCD patients. However, all sperm parameters during HU treatment were affected [47]. There were no incidents of azoospermia in five patients, although a marked decrease in sperm density during the HU treatment compared to before the HU treatment was reported. Interrupting HU treatment did not help recuperate the sperm parameters to initial levels.

However, before HU was established as a standard of care to treat SCD, subfertile range sperm parameters had been reported in patients. More recent studies have reported at least one abnormal sperm parameter in about 90% of patients [47].

HU treatment, even in low doses, exacerbates sperm parameters abnormalities in SCD patients. Therefore, routine seminal fluid parameters assessment is recommended to monitor sperm parameter changes during treatment with HU.

Treatments Available

For patients who have abnormal spermatogenesis due to their underlying condition or treatment of the conditions, the option of fertility preservation can be considered. The “optimal” age for fertility preservation is still a discussion. Below are some of the options available [46]-

Erectile dysfunction can be managed with penile implants effectively

Testicular tissue cryopreservation

Gonadal shielding

Sperm cryopreservation

Testicular sperm extraction

Electroejaculation- electrical current to trigger ejaculation.

Symptoms of hypogonadism can be treated with testosterone undecanoate injections12 and clomiphene13

In prepubertal males, patients have very limited experimental options, for example, removal and preservation of part of the testicle [47]. However, there have been no reports of live human births from re-implanted testicular tissue yet.

Counseling about infertility risk associated with the disease and treatments, and options for fertility preservation is important in these situations. Many unresolved ethical dilemmas arise for pediatric patients regarding counseling about fertility issues and preservation. The first dilemma is with whom the responsibility of making the decision should rest. Although some guidelines consider it should be parents, often patients (mostly children in case of SCD) and parents may have different opinions and choices. The American Academy of Pediatrics has published guidelines encouraging healthcare providers to discuss the issues and options with patients and guardians [48].

Since fertility preservation may not be feasible in all cases of SCD, regular monitoring for sperm abnormalities during HU therapy has been suggested.

Conclusions

HU has significantly improved the treatment outcomes in SCD patients. However, some concerns regarding the cytotoxic effects of HU on spermatogenesis emerge. Extensive research is required to evaluate the before and after treatment sperm parameters and the effects of treatment with HU on spermatogenesis.

Newer medical advances have improved survival rates and reduced disease-related morbidity in SCD patients, bringing reproductive issues to the forefront. Prospective, large population-based studies among patients with SCD are required to determine cellular and functional impairment of fertility and evaluate the impact of HU therapy on the impairment.

The clinical practice and future research should be streamlined to focus on improving the quality of life along with the prognosis of the patients. The patient-centric research will help in better management and treatment of patients with SCD with HU therapy.

[regenerationcenterthailand]

New Stem Cell Therapy Approved for Blood Cancers

The European Medicines Agency (EMA) has recommended conditional approval of a novel cell therapy aimed at treating adults with hematologic malignancies. This therapy utilizes allogeneic umbilical cord-derived CD34- cells and is designed for patients requiring allogeneic hematopoietic stem cell transplantation (allo-HSCT) when no suitable donor cells are available. Trials have shown promising results in clinical studies, with 84% of patients achieving neutrophil engraftment within 20 days and 68% achieving platelet engraftment within 40 days. The EMA's Committee for Advanced Therapies concluded that the benefits of the treatment outweigh the risks for patients with these blood cancers. However, further studies are required to confirm its long-term safety and efficacy, including randomized controlled trials and patient registry studies. The therapy is supported by the EMA's Priority Medicines (PRIME) scheme, which aims to expedite the development of treatments addressing unmet medical needs.

[102ki]

zenhoui kyun could be huge

[isabelamarina766]

Hematopoietic stem cell transplantation (HSCT) has emerged as a promising therapeutic approach for individuals diagnosed with multiple sclerosis (MS).

[greenwoodbotanics10]

MS Mysteries Unlocked: Early Clues, Lifespan Secrets, and a Radical Cure?

MS Mysteries Unlocked Multiple Sclerosis (MS) is a complex and unpredictable disease—but what if we could crack its code? From strange first symptoms to groundbreaking stem cell treatments, here’s what science reveals (and what still remains a mystery).  The Weird First Signs of MS Your Doctor Warned You About MS doesn’t always announce itself loudly. Instead, it whispers through bizarre…